Predict your next investment

HEALTHCARE | Drug Development
syndax.com

See what CB Insights has to offer

Competitors

21

Business Relationships

10

Service Providers

4

Syndax Pharmaceuticals Competitors & Alternatives

21 Competitors

Syndax Pharmaceuticals has 21 competitors. Syndax Pharmaceuticals's competitors are ISA Pharmaceuticals, Rafael Pharmaceuticals, Acorda Therapeutics, Esperance Pharmaceuticals, OncoMed Pharmaceuticals and more.

Latest Funding

Companies

Investment Stage

Total Funding

Mosaic
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

Location

7/14/2021

Unattributed VC - III

$44.3M

Netherlands

6/21/2021

Merger

$37.05M

New Jersey

4/27/2020

Loan

$144.54M

New York

7/12/2019

Convertible Note

$22.7M

Texas

4/23/2019

Acq - P2P

$294.6M

California

8/17/2018

Series E

$2.9M

Alabama

12/1/2015

Dead

$55.15M

Germany

7/31/2014

IPO

Sweden

10/15/2013

Acquired

$16.45M

United Kingdom

10/7/2013

Acquired

$20M

Maryland

Latest Funding

7/14/2021

6/21/2021

4/27/2020

7/12/2019

4/23/2019

8/17/2018

12/1/2015

7/31/2014

10/15/2013

10/7/2013

Companies

Investment Stage

Unattributed VC - III

Merger

Loan

Convertible Note

Acq - P2P

Series E

Dead

IPO

Acquired

Acquired

Total Funding

$44.3M

$37.05M

$144.54M

$22.7M

$294.6M

$2.9M

$55.15M

$16.45M

$20M

Mosaic

Location

Netherlands

New Jersey

New York

Texas

California

Alabama

Germany

Sweden

United Kingdom

Maryland

Syndax Pharmaceuticals Service Providers

4 Service Providers

Syndax Pharmaceuticals has 4 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

IPO

Investment Bank

Financial Advisor

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Subscribe to see more

Associated Rounds

IPO

Subscribe to see more

Subscribe to see more

Provider Type

Investment Bank

Subscribe to see more

Subscribe to see more

Service Type

Financial Advisor

Subscribe to see more

Partnership data by VentureSource

Syndax Pharmaceuticals Partners & Customers

10 Partners and customers

Syndax Pharmaceuticals has 10 strategic partners and customers. Syndax Pharmaceuticals recently partnered with Incyte on September 9, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

9/28/2021

Licensee

Incyte

United States

Syndax collaborates with Incyte to develop monoclonal antibody

Syndax Pharmaceuticals and Incyte have signed an exclusive global partnership and licence agreement to develop and market the former 's anti-CSF-1R monoclonal antibody , axatilimab .

3

5/30/2018

Partner

Nektar Therapeutics

United States

Syndax, Nektar Therapeutics announce immuno-oncology clinical trial collaboration

The partnership will assess the safety and efficacy of Nektar Therapeutics 's NKTR-214 , a CD122-biased agonist , in combination with entinostat , Syndax Pharmaceuticals 's oral , small molecule Class 1 specific HDAC inhibitor , in patients with metastatic melanoma who have previously progressed on treatment with an anti-PD-1 agent .

2

2/1/2018

Partner

AstraZeneca

United Kingdom

Syndax partners with AstraZeneca for immuno-oncology clinical trials

Under the terms of the agreement , Syndax Pharmaceuticals and AstraZeneca will collaborate on a non-exclusive basis to evaluate the combination of the two drugs in multiple solid tumor types .

8

1/10/2018

Partner

Roche Holding

Switzerland

Subscribe to see more

Subscribe to see more

10

1/4/2016

Partner

Pfizer

United States

Subscribe to see more

Subscribe to see more

10

Date

9/28/2021

5/30/2018

2/1/2018

1/10/2018

1/4/2016

Type

Licensee

Partner

Partner

Partner

Partner

Business Partner

Incyte

Nektar Therapeutics

AstraZeneca

Roche Holding

Pfizer

Country

United States

United States

United Kingdom

Switzerland

United States

News Snippet

Syndax collaborates with Incyte to develop monoclonal antibody

Syndax Pharmaceuticals and Incyte have signed an exclusive global partnership and licence agreement to develop and market the former 's anti-CSF-1R monoclonal antibody , axatilimab .

Syndax, Nektar Therapeutics announce immuno-oncology clinical trial collaboration

The partnership will assess the safety and efficacy of Nektar Therapeutics 's NKTR-214 , a CD122-biased agonist , in combination with entinostat , Syndax Pharmaceuticals 's oral , small molecule Class 1 specific HDAC inhibitor , in patients with metastatic melanoma who have previously progressed on treatment with an anti-PD-1 agent .

Syndax partners with AstraZeneca for immuno-oncology clinical trials

Under the terms of the agreement , Syndax Pharmaceuticals and AstraZeneca will collaborate on a non-exclusive basis to evaluate the combination of the two drugs in multiple solid tumor types .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

3

2

8

10

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.